Show simple item record

dc.contributor.authorAltieri, Dario C.
dc.date2022-08-11T08:09:37.000
dc.date.accessioned2022-08-23T16:37:42Z
dc.date.available2022-08-23T16:37:42Z
dc.date.issued2008-10-22
dc.date.submitted2009-10-15
dc.identifier.citation<p>Oncogene. 2008 Oct 20;27(48):6276-84. <a href="http://dx.doi.org/10.1038/onc.2008.303">Link to article on publisher's site</a></p>
dc.identifier.issn1476-5594 (Electronic)
dc.identifier.doi10.1038/onc.2008.303
dc.identifier.pmid18931693
dc.identifier.urihttp://hdl.handle.net/20.500.14038/39083
dc.description.abstractA little over 10 years after its discovery in 1997, the small inhibitor of apoptosis (IAP) protein, survivin, continues to generate intense interest and keen attention from disparate segments of basic and disease-related research. Part of this interest reflects the intricate biology of this multifunctional protein that intersects fundamental networks of cellular homeostasis. Part is because of the role of survivin as a cancer gene, which touches nearly every aspect of the disease, from onset to outcome. And part is due to the potential value of survivin for novel cancer diagnostics and therapeutics, which have already reached the clinic, and with some promise. Grappling with emerging new signaling circuits in survivin biology, and their implications in cancer, will further our understanding of this nodal protein, and open fresh opportunities for translational oncology research.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=18931693&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683067/
dc.subjectHumans
dc.subjectMicrotubule-Associated Proteins
dc.subjectNeoplasm Proteins
dc.subjectNeoplasms
dc.subjectSignal Transduction
dc.subjectSubcellular Fractions
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleNew wirings in the survivin networks
dc.typeJournal Article
dc.source.journaltitleOncogene
dc.source.volume27
dc.source.issue48
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/1901
dc.identifier.contextkey1036644
html.description.abstract<p>A little over 10 years after its discovery in 1997, the small inhibitor of apoptosis (IAP) protein, survivin, continues to generate intense interest and keen attention from disparate segments of basic and disease-related research. Part of this interest reflects the intricate biology of this multifunctional protein that intersects fundamental networks of cellular homeostasis. Part is because of the role of survivin as a cancer gene, which touches nearly every aspect of the disease, from onset to outcome. And part is due to the potential value of survivin for novel cancer diagnostics and therapeutics, which have already reached the clinic, and with some promise. Grappling with emerging new signaling circuits in survivin biology, and their implications in cancer, will further our understanding of this nodal protein, and open fresh opportunities for translational oncology research.</p>
dc.identifier.submissionpathoapubs/1901
dc.contributor.departmentDepartment of Cancer Biology and the Cancer Center
dc.source.pages6276-84


This item appears in the following Collection(s)

Show simple item record